Vitamin K Epoxide Reductases
"Vitamin K Epoxide Reductases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
OXIDOREDUCTASES which mediate vitamin K metabolism by converting inactive vitamin K 2,3-epoxide to active vitamin K.
Below are MeSH descriptors whose meaning is more general than "Vitamin K Epoxide Reductases".
Below are MeSH descriptors whose meaning is more specific than "Vitamin K Epoxide Reductases".
This graph shows the total number of publications written about "Vitamin K Epoxide Reductases" by people in this website by year, and whether "Vitamin K Epoxide Reductases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Vitamin K Epoxide Reductases" by people in Profiles.
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. Clin Pharmacol Ther. 2019 06; 105(6):1477-1491.
Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans. J Thromb Haemost. 2017 04; 15(4):735-743.
Effect of CYP2C9 and VKORC1 Gene Variants on Warfarin Response in Patients with Continuous-Flow Left Ventricular Assist Devices. ASAIO J. 2016 Sep-Oct; 62(5):558-64.
Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. Pharmacogenomics. 2015; 16(3):217-25.
Genotype-guided dosing of vitamin K antagonists. N Engl J Med. 2014 05 01; 370(18):1763.
Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. Pharmacogenomics J. 2014 Jun; 14(3):223-8.
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013 Aug 31; 382(9894):790-6.
Pathway analysis of genome-wide data improves warfarin dose prediction. BMC Genomics. 2013; 14 Suppl 3:S11.
VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. Thromb Haemost. 2013 Jun; 109(6):1045-50.
The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol. 2012 Jul; 8(4):563-76.